Status:
COMPLETED
Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)
Lead Sponsor:
Shengjing Hospital
Conditions:
Breast Cancer
Eligibility:
All Genders
Phase:
NA
Brief Summary
To investigate this regression model by injecting and tracing carbon nanoparticles (CNs) into the fusion node prior to NAC in patients with breast cancer.
Detailed Description
Guided by ultrasound, 0.3 mL of CNs suspension was injected in a fusion node prior to NAC in 110 patients with local advanced breast cancer. Patients underwent breast surgery and total axillary lymph ...
Eligibility Criteria
Inclusion
- invasive ductal carcinoma diagnosed by biopsy;
- clinically positive node diagnosed by contrast enhance computer tomography (CECT), the number of strengthened nodes at Level I ≥ 1 with the longest diameter of the strengthened node ≥ 2cm;
- NAC regimen followed the NCCN guideline;
- no prior history of breast cancer or other malignancies.
Exclusion
- the cycle number of neo-adjuvant chemotherapy is equal to or less than 2
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2018
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT03355261
Start Date
July 1 2014
End Date
July 1 2018
Last Update
February 20 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Hospital of Jilin University
Changchun, Jilin, China
2
the First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China, 110001
3
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004